{"nctId":"NCT00654381","briefTitle":"Japanese P III vs Voglibose and Placebo","startDateStruct":{"date":"2008-04"},"conditions":["Diabetes Mellitus, Type 2"],"count":561,"armGroups":[{"label":"voglibose 0.2 mg three times a day (TID)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: voglibose"]},{"label":"BI 1356 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1356"]},{"label":"BI 1356 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1356"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: voglibose placebo","Drug: BI 1356 placebo"]}],"interventions":[{"name":"BI 1356","otherNames":[]},{"name":"BI 1356","otherNames":[]},{"name":"voglibose placebo","otherNames":[]},{"name":"BI 1356 placebo","otherNames":[]},{"name":"voglibose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy has to be stable for at least 10 weeks before Visit 1.\n2. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at Visit 3 (beginning of the 2-week placebo run-in phase)\n3. Age: \\>= 20 and \\<= 80\n4. Body Mass Index (BMI) \\<= 40 kg/m2\n\nExclusion criteria:\n\n1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months before Visit 1\n2. Impaired hepatic function\n3. History of severe allergy/hypersensitivity\n4. Treatment with anti-diabetic, anti obesity drugs, etc 3 months before Visit 1\n5. Fasting blood glucose \\>240 mg/dl (=13.3 mmol/L) at Visits 2 or 3","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 12","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.08"},{"groupId":"OG001","value":"-0.24","spread":"0.06"},{"groupId":"OG002","value":"-0.25","spread":"0.06"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 26","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.07"},{"groupId":"OG001","value":"-0.19","spread":"0.07"},{"groupId":"OG002","value":"0.19","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Relative Efficacy Response of HbA1c at Week 12","description":"HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Efficacy Response of HbA1c at Week 26","description":"HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Efficacy Response of HbA1c at Week 52","description":"HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"2.5"},{"groupId":"OG001","value":"-12.3","spread":"1.9"},{"groupId":"OG002","value":"-13.0","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"2.4"},{"groupId":"OG001","value":"-7.8","spread":"2.4"},{"groupId":"OG002","value":"2.0","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52","description":"Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"2.7"},{"groupId":"OG001","value":"-5.9","spread":"2.7"}]}]}]},{"type":"PRIMARY","title":"Examination of Long-term Safety of Linagliptin (52-week Treatment)","description":"The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":80},"commonTop":["Nasopharyngitis","Back pain","Constipation","Diabetes mellitus","Diarrhoea"]}}}